Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
The target demographic will be those between the ages of 30 and 65 years
It has signed an MoU with Plan India to expand its reach to Karnataka
The objective behind introducing this extraordinary digital campaign is to spread awareness among Gen X and Z for the need of breast self-examination
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
